On June 12, the Supreme Court decided Sandoz v. Amgen, which presented the Justices with multiple significant questions about the correct interpretation and application of the biosimilars statute, the Biologics Price Competition and Innovation Act. Goodwin will host a Webinar, including a lively discussion about the case as partners Elaine Herrmann Blais and Willy Jay analyze the outcome and discuss what is likely to happen next, along with how the decision impacts biosimilars strategy going forward.
For more information and to register for this event, please click here.
Elaine Herrmann BlaisPartner
William M. JayPartnerCo-Chair, Washington, DC Office